Skip to main content

Table 1 Demographic and clinical features of patients with RA according to Anti-PAD antibody status

From: Smoking is not linked to the development of anti-peptidylarginine deiminase 4 autoantibodies in rheumatoid arthritis

 

PAD negative (P0) (N = 206)

PAD4 Ab only (P4) (N = 34)

PAD3/4 Ab (XR)

(N = 34)

p-value

P0 vs P4

p-value

P0 vs XR

p-value

P4 vs XR

Female sex- N (%)

163 (79%)

27 (79%)

28 (82%)

0.99

0.66

0.76

Race- N (%)

   

0.99

0.91

0.95

 Caucasian

165 (80%)

28 (82.4%)

27 (79%)

   

 African American

27 (13%)

4 (11.8%)

4 (12%)

   

 Asian/Other

14 (7%)

2 (6%)

3 (9%)

   

Age- median (IQR)

57 (49–66)

55 (47–68)

51.5 (46–64)

0.70

0.14

0.33

Disease duration (yrs) - median (IQR)

6 (2–12)

15.5 (8–27)

15.5 (7–26)

< 0.01

< 0.01

0.77

Ever smoking- N (%)

95 (47%)

16 (47%)

12 (35%)

0.96

0.22

0.32

Current smoking- N (%)

24 (12%)

3 (8.8%)

0 (0%)

0.62

0.04

0.08

CCP positive- N (%)

116 (57%)

30 (88.2%)

30 (88.2%)

< 0.01

< 0.01

1.0

Shared Epitope- N (%)

112 (54%)

28 (82.4%)

22 (64.7%)

< 0.01

0.26

0.10

Erosions- N (%)

N = 268

88 (43%)

17 (54.8%)

22 (65%)

0.24

0.02

0.42

CDAI- median (IQR)

7.9 (3–16)

7 (2.8–11.5)

3.7 (1.5–9.5)

0.37

0.04

0.21

On a DMARD- N (%)

184 (90%)

28 (82%)

28 (82%)

0.21

0.20

1.0

On methotrexate- N (%)

127 (63%)

20 (59%)

24 (71%)

0.73

0.33

0.31

On a biologic- N (%)

89 (44%)

17 (50%)

16 (47%)

0.49

0.71

0.81